The Effects of Two Synthetic Glycoprotein II b/III a Antagonists, Ro 43-8857 and L-700,462, on Platelet Aggregation and Bleeding in Guinea-Pigs and Dogs: Evidence that Ro 43-8857 Is Orally Active

Summary

In vitro platelet aggregation studies in whole blood were used to define the species-specificity profile of two synthetic GP-IIb/IIIa antagonists, Ro 43-8857 and L-700,462. Aggregation of rhesus monkey platelets was inhibited with a similar potency to human platelets, whereas both compounds were poor antagonists in mini-pig, rabbit or hamster blood. Compared to human platelets, Ro 43-8857 was 2-3-fold less active as an inhibitor of dog and guinea-pig platelet aggregation, whereas L-700,462 was, respectively, 4- and 14-fold less active in these species.

In vivo investigations with these two compounds were performed in anesthetized guinea-pigs and conscious dogs, with bleeding times measured on small mesenteric arteries or on the inner jowl respectively. Ex vivo ADP-induced whole blood platelet aggregation was completely inhibited in guinea-pigs by Ro 43-8857 following intravenous administration of 0.1 mg/kg and intraduodenal administration of 3 mg/kg, with a duration of action exceeding 5 hours. Mesenteric bleeding times were prolonged by Ro 43-8857 only at doses causing supra-maximal inhibition of aggregation, suggesting these two effects could be partially dissociated. L-700,462 (3 mg/kg i. v.) was shorter acting than Ro 43-8857 in guinea-pigs (duration ~1 hour) and the antiaggregatory effect was accompanied by mesenteric bleeding time prolongations. In conscious dogs, ex vivo aggregation was inhibited to —80% by Ro 43-8857 (0.3 mg/kg i. v. or 10 mg/kg p. o.) and L-700,462 (1 mg/kg i.v.). However, bleeding time prolongations accompanied these anti-aggregatory effects with both compounds.

In conclusion, we have shown clear differences between two synthetic GP-IIb/IIIa antagonists, both in terms of their species-specificity in vitro and in terms of their in vivo profile, and in particular the propensity to promote bleeding from mesenteric arteries in guinea-pigs. However, the ability of Ro 43-8857 to discriminate between anti-aggregatory and bleeding effects was not evident when the bleeding time measurements were performed on the dog jowl. This suggests that the species and/or vessels on which the bleeding time is performed, is also an important consideration when characterizing and comparing antiplatelet compounds, even with drugs acting via the same mechanism. These results are relevant for the future design of in vivo animal experiments to characterize this new class of compounds and in the interpretation of the data obtained to the clinical situation. The animal models described here are well suited for comparative studies of different GP-IIb/IIIa antagonists, providing information on in vivo potency, duration of action and effect-bioavailability following different routes of administration.

Orally active GP-IIb/IIIa antagonists have not previously been described in the literature. The long duration of action and oral activity shown by Ro 43-8857 suggests a potential use of such compounds in arterial thrombotic disorders requiring chronic therapy.

• References

• 1 Harfenist EJ, Packham MA, Mustard JF. Effects of the cell adhesion peptide, Arg-Gly-Asp-Ser, on responses of washed platelets from humans, rabbits and rats. Blood 1988; 71: 132-136
• 2 Verhallen PFJ, Barth M. Species comparison of anti-aggregatory properties of three fibrinogen receptor antagonists: RGDS, echistatin and the carboxyterminal dodecapeptide of the fibrinogen gamma-chain. Thromb Haemostas 1991; 65: 1144
• 3 Cox D, Motoyama Y, Seki J, Aoki T, Dohy M, Yoshida K. Pentamidine: a non-peptide GP-IIb/IIIa antagonist – In vitro studies on platelets from humans and other species. Thromb Haemostas 1992; 68: 731-736
• 4 Cook NS, Zerwes H-G, Tapparelli C, Powling M, Singh J, Metternich R, Hagenbach A. Platelet aggregation and fibrinogen binding in human, rhesus monkey, guinea-pig, hamster and rat blood: activation by ADP and a thrombin receptor peptide and inhibition by glycoprotein IIb/IIIa antagonists. Thromb Haemostas 1993; 70: 531-539
• 5 Hadváry P, Alig L, Edenhofer A, Muller M, Sakariassen K, Steiner B, Weller T, Baumgartner HR. Selective inhibitors of GP-IIb/IIIa from different chemical classes preferentially inhibit thrombus formation at high shear rate. Thromb Haemostas 1991; 65: 813
• 6 Alig L, Edenhofer A, Hadváry P, Hürzeler M, Knopp D, Müller M, Steiner B, Trzeciak A, Weller T. Low molecular weight, non-peptide fibrinogen receptor antagonists. J Med Chem 1992; 35: 4393-4407
• 7 Rodgers RPC, Levin J. A critical reappraisal of the bleeding time. Sem Thromb Hemostas 1990; 16: 1-20
• 8 Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991; 77: 2547-2552
• 9 Gold HK, Gimple LW, Yasuda T, Leinbach RC, Werner W, Holt R, Jordan R, Berger H, Collen D, Coller BS. Pharmacodynamic study of F(ab’)₂ fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990; 86: 651-659
• 10 Ellis SG, Navetta FI, Tcheng JT, Weisman HF, Wang AL, Pitt B, Topol EJ. Antiplatelet GP-IIb/IIIa (7E3) antibody in elective PTC A: safety and inhibition of platelet function. Circulation 1990; 82: III-191
• 11 Anderson HV, Revana M, Rosales O, Brannigan L, Stuart Y, Weisman H, Willerson JT. Intravenous administration of monoclonal antibody to platelet GP-IIb/IIIa receptor to treat abrupt closure during coronary angioplasty. Am J Cardiol 1992; 69: 1373-1376
• 12 Hanson SR, Kotzé HF, Harker LA, Scarborough RM, Charo IF, Philips DR. Potent antithrombotic effects of novel peptide antagonists of platelet glycoprotein (GP) IIb/IIIa. Thromb Haemostas 1991; 65: 813
• 13 Tschopp JF, Driscoll EM, Mu D-X, Black SC, Pierschbacher MD, Lucchesi BR. Inhibition of reocclusion and acceleration of thrombolysis by an RGD peptide without bleeding time prolongation. Blood 1992; 80 (Suppl. 01) 320a
• 14 O’Laughlin JC, Hoftiezer JW, Mahoney JP, Ivey KJ. Does aspirin prolong bleeding from gastric biopsies in man?. Gastrointest Endosc 1981; 27: 1-5
• 15 Chung JYL, Zhao D, Hughes DL, Grabowski EJJ. Selective functionalization of (S)-tyrosine. Development of a highly efficient synthesis of fibrinogen receptor antagonist L-700, 462. Proceedings of the 204^th American Chemical Society National Meeting Washington DC: 1992. abstract. 271
• 16 Peerlinck K, De LepeleireI, Goldberg M, Paneblanco D, Vermylen J, Arnout J. Activity and safety of L-700,462, a selective GP-IIb/IIIa antagonist, in healthy volunteers. Circulation 1992; 86 (Suppl. 01) 1-866
• 17 Sixma JJ, Pronk A, Nievelstein PFEM, Zwaginga JJ, Hindriks GA, Tijburg PNM, Banga JD, de GrootPG. Platelet adhesion to extracellular matrices of cultured cells. Ann NY Acad Sci 1991; 614: 181-192
• 18 Hantgan RR, Endenburg SC, Cavero I, Marguerie G, Uzan A, Sixma JJ, de GrootPG. Inhibition of platelet adhesion to fibrin (ogen) in flowing blood by Arg-Gly-Asp and fibrinogen γ-chain carboxy terminal peptides. Thromb Haemostas 1992; 68: 694-700
• 19 Saelman EUM, Hese KM, Nieuwenhius K, Uzan A, Cavero I, Marguerie G, Sixma JJ, de GrootPG. Aggregate-formation is more strongly inhibited at high shear rates by dRGDW, a synthetic RGD-containing peptide. Thromb Haemostas. in press
• 20 Ruggeri ZM. von Willebrand Factor as a target for antithrombotic intervention. Circulation 1992; 86 (Suppl. 03) III26-III29
• 21 Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors: A dual role for glycoprotein IIb/IIIa (integrin α_IIbβ3) mediated by fibrinogen and glycoprotein Ib-von Willebrand Factor. J Biol Chem 1992; 267: 11300-11306
• 22 Kouns WC, Kirchhofer D, Hadváry P, Edenhofer A, Weller T, Pfenninger G, Baumgartner HR, Jennings LK, Steiner B. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood 1992; 80: 2539-2547
• 23 Kouns WC, Weller T, Hadváry P, Jennings LK, Steiner B. Identification of a peptidomimetic inhibitor with minimal effects on the conformation of GP-IIb/IIIa. Blood 1992; 80 (Suppl. 01) abstract. 650
• 24 Tschopp JF, Bell DJ, Bunting S, Burnier JP, Cheng S, Craig WS, Dixon DB, Gadeck T, Mazur C, McDowell RS, Mullen DG, Napier MA, Pierschbacher MD. Novel RGD-based glycoprotein IIb/IIIa receptor antagonists as antithrombotics. Blood 1992; 80 (Suppl. 01) 320a (abstract 1272)
• 25 Nichols AJ, Ruffolo RR, Huffman WF, Poste G, Samanen J. Development of GP-IIb/IIIa antagonists as antithrombotic drugs. Trends Pharmacol Sci 1992; 13: 413-417
• 26 Willette RN, Sauermelch CF, Rycyna R, Sakar S, Feuerstein GZ, Nichols AJ, Ohlstein EH. Antithrombotic effects of a platelet fibrinogen receptor antagonist in a canine model of carotid artery thrombosis. Stroke 1992; 23: 703-711
• 27 Imura Y, Stassen J-M, Vreys I, Lesaffre E, Gold HK, Collen D. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model. Thromb Haemostas 1992; 68: 336-340
• 28 Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GP-IIb/IIIa receptor: Correlation with bleeding time, platelet aggregation, and blockade of GP-IIb/IIIa receptors. Lab Invest 1989; 80: 1766-1774
• 29 Shebuski RJ, Ramjit DR, Sitko GR, Lumma PK, Garsky VM. Prevention of canine coronary artery thrombosis with echistatin, a potent inhibitor of platelet aggregation from the venom of the viper, Echis carinatus. Thromb Haemostas 1990; 64: 576-581
• 30 Song A, Scarborough RM, Phillips DR, Adelman B, Strony J. Integrellin enhances fibrinolysis and prevents acute arterial reocclusion following thrombolysis in a canine anodal current model with high grade stenosis. Circulation 1992; 86 (Suppl. 01) 1-410
• 31 Imura Y, Stassen J-M, Bunting S, Stockmans F, Collen D. Antithrombotic properties of L-Cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-Sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model. Blood 1992; 80: 1247-1253
• 32 Herbert JM, Bernat A, Maffrand JP. Importance of platelets in experimental venous thrombosis in the rat. Blood 1992; 80: 2281-2286
• 33 Frank JD, Gould RJ, Schaffer LW, Davidson JT, Gibson RE, Patrick DH, Vonderfecht SL, Cartwright ME. Immunocytochemical localization of platelets in baboon hepatic sinusoids using monoclonal mouse anti-human platelet glycoprotein Ilia following induction of thrombocytopenia. Histocytochem 1992; 97: 355-360
• 34 Suzuki M, Kawakatsu T, Nagata H, Hamamoto K, Iwata K, Ohga S, Nomura S, Kokawa T, Yasunaga K. Effects of injected antibody against the platelet glycoprotein II b/III a complex on monkey platelet fibrinogen. Thromb Haemostas 1992; 67: 578-581
• 35 Harrison P, Wilboum B, Cramer E, Faint R, Mackie IJ, Bhattacharya S, Lahiri A, Tenza D, Machin SJ, Savidge GF. The influence of therapeutic blocking of GP-IIb/IIIa on platelet α-granular fibrinogen. Br J Haematol 1992; 82: 721-728